eCite Digital Repository

Health care cost analysis in a population-based inception cohort of Inflammatory Bowel Disease patients in the first year of diagnosis


Niewiadomski, O and Studd, C and Hair, C and Wilson, J and McNeill, J and Knight, R and Prewett, E and Dabkowski, P and Dowling, D and Alexander, S and Allen, B and Tacey, M and Connell, W and Desmond, PR and Bell, S, Health care cost analysis in a population-based inception cohort of Inflammatory Bowel Disease patients in the first year of diagnosis, Journal of Crohn's and Colitis, 9, (11) pp. 988-996. ISSN 1873-9946 (2015) [Refereed Article]

Copyright Statement

Copyright 2015 Europena Crohn's and Colitis Organisation

DOI: doi:10.1093/ecco-jcc/jjv117


BACKGROUND: There are limited prospective population-based data on the health care cost of IBD in the post-biologicals era. A prospective registry that included all incident cases of inflammatory bowel disease [IBD] was established to study disease progress and health cost.

AIM: To prospectively assess health care costs in the first year of diagnosis among a well-characterised cohort of newly diagnosed IBD patients.

METHOD: Incident cases of IBD were prospectively identified in 2007-2008 and 2010-2013 from multiple health care providers, and enrolled into the population-based registry. Health care resource utilisation for each patient was collected through active surveillance of case notes and investigations including specialist visits, diagnostic tests, medications, medical hospitalisation, and surgery.

RESULTS: Off 276 incident cases of IBD, 252 [91%] were recruited to the registry, and health care cost was calculated for 242 (146 Crohn's disease [CD] and 96 ulcerative colitis [UC] patients). The median cost in CD was higher at A$5905 per patient (interquartile range [IQR]: A$1571-$91,324) than in UC at A$4752 [IQR: A$1488-A$58,072]. In CD, outpatient resources made up 55% of all cost, with medications accounting for 32% of total cost [15% aminosalicylates, 15% biological therapy], followed by surgery [31%], and diagnostic testing [21%]. In UC, medications accounted for 39% of total cost [of which 37% was due to 5-aminosalicylates, and diagnostics 29%; outpatient cost contributed 71% to total cost.

CONCLUSION: In the first year of diagnosis, outpatient resources account for the majority of cost in both CD and UC. Medications are the main cost driver in IBD.

Item Details

Item Type:Refereed Article
Keywords:Crohn’s disease, Inflammatory bowel disease, health cost analysis, population-based, ulcerative colitis
Research Division:Health Sciences
Research Group:Health services and systems
Research Field:Health services and systems not elsewhere classified
Objective Division:Health
Objective Group:Evaluation of health and support services
Objective Field:Health policy evaluation
UTAS Author:Studd, C (Dr Corrie Studd)
ID Code:119037
Year Published:2015
Web of Science® Times Cited:35
Deposited By:Menzies Institute for Medical Research
Deposited On:2017-07-25
Last Modified:2017-11-08

Repository Staff Only: item control page